Unexpected solution behaviour of ester-functionalized half-sandwich Ru(II) and Ir(III) complexes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26620%2F21%3APU142121" target="_blank" >RIV/00216305:26620/21:PU142121 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15310/21:73609430

Výsledek na webu

<a href="https://pubs.rsc.org/en/content/articlelanding/2021/DT/D1DT00466B" target="_blank" >https://pubs.rsc.org/en/content/articlelanding/2021/DT/D1DT00466B</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1039/d1dt00466b" target="_blank" >10.1039/d1dt00466b</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Unexpected solution behaviour of ester-functionalized half-sandwich Ru(II) and Ir(III) complexes

Popis výsledku v původním jazyce

Complexes [Ru(eta(6)-pcym)(bpy(dca))Cl]PF6 (Ru-dca) and [Ir(eta(5)-Cp*)(bpy(dca))Cl]PF6 (Ir-dca) were developed as model compounds for the investigation of multi-targeted ester-functionalized half-sandwich ruthenium(ii) and iridium(iii) complexes; pcym = 1-methyl-4-(propan-2-yl)benzene (p-cymene), bpy(dca) = 2,2 '-bipyridine-4,4 '-diyldimethanediyl bis(dichloroacetate), Cp* = pentamethylcyclopentadienyl. Aiming to understand the in-solution behaviour of these first-in-class complexes containing the pyruvate dehydrogenase kinase inhibitor dichloroacetate (dca) as the terminal bioactive substituent, several experiments were performed under aqueous conditions for Ru-dca and Ir-dca, as well as for compounds [Ru(eta(6)-pcym)(bpy(OH))Cl]PF6 (Ru-OH) and [Ir(eta(5)-Cp*)(bpy(OH))Cl]PF6 (Ir-OH), and acetyl analogues [Ru(eta(6)-pcym)(bpy(ac))Cl]PF6 (Ru-ac) and [Ir(eta(5)-Cp*)(bpy(ac))Cl]PF6 (Ir-ac) bearing a different (biologically inactive) terminal substituent; bpy(OH) = 2,2 '-bipyridine-4,4 '-diyldimethanol, bpy(ac) = 2,2 '-bipyridine-4,4 '-diyldimethanediyl diacetate. The experiments were also conducted in the presence of porcine liver esterase (PLE). All the six complexes were characterized by relevant techniques (e.g., NMR and mass spectrometry), including a single-crystal X-ray analysis of complexes Ru-dca, Ru-ac, Ru-OH and Ir-OH. Although designed as model compounds, Ru-dca, Ir-dca, Ru-OH and Ir-OH were also screened for their antiproliferative activity in four human cancer cell lines (HCT116 colon carcinoma, MDA-MB-231 and MCF-7 breast adenocarcinomas, DU145 prostate carcinoma), where the tested complexes did not show any effect (IC50 > 100 mu M).

Název v anglickém jazyce

Unexpected solution behaviour of ester-functionalized half-sandwich Ru(II) and Ir(III) complexes

Popis výsledku anglicky

Complexes [Ru(eta(6)-pcym)(bpy(dca))Cl]PF6 (Ru-dca) and [Ir(eta(5)-Cp*)(bpy(dca))Cl]PF6 (Ir-dca) were developed as model compounds for the investigation of multi-targeted ester-functionalized half-sandwich ruthenium(ii) and iridium(iii) complexes; pcym = 1-methyl-4-(propan-2-yl)benzene (p-cymene), bpy(dca) = 2,2 '-bipyridine-4,4 '-diyldimethanediyl bis(dichloroacetate), Cp* = pentamethylcyclopentadienyl. Aiming to understand the in-solution behaviour of these first-in-class complexes containing the pyruvate dehydrogenase kinase inhibitor dichloroacetate (dca) as the terminal bioactive substituent, several experiments were performed under aqueous conditions for Ru-dca and Ir-dca, as well as for compounds [Ru(eta(6)-pcym)(bpy(OH))Cl]PF6 (Ru-OH) and [Ir(eta(5)-Cp*)(bpy(OH))Cl]PF6 (Ir-OH), and acetyl analogues [Ru(eta(6)-pcym)(bpy(ac))Cl]PF6 (Ru-ac) and [Ir(eta(5)-Cp*)(bpy(ac))Cl]PF6 (Ir-ac) bearing a different (biologically inactive) terminal substituent; bpy(OH) = 2,2 '-bipyridine-4,4 '-diyldimethanol, bpy(ac) = 2,2 '-bipyridine-4,4 '-diyldimethanediyl diacetate. The experiments were also conducted in the presence of porcine liver esterase (PLE). All the six complexes were characterized by relevant techniques (e.g., NMR and mass spectrometry), including a single-crystal X-ray analysis of complexes Ru-dca, Ru-ac, Ru-OH and Ir-OH. Although designed as model compounds, Ru-dca, Ir-dca, Ru-OH and Ir-OH were also screened for their antiproliferative activity in four human cancer cell lines (HCT116 colon carcinoma, MDA-MB-231 and MCF-7 breast adenocarcinomas, DU145 prostate carcinoma), where the tested complexes did not show any effect (IC50 > 100 mu M).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10402 - Inorganic and nuclear chemistry

Projekt

<a href="/cs/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Dalton Transactions

ISSN

1477-9226

e-ISSN

1477-9234

Svazek periodika

50

Číslo periodika v rámci svazku

23

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

8017-8028

Kód UT WoS článku

000651841500001

EID výsledku v databázi Scopus

2-s2.0-85108000125